Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension

International Journal of Pharmaceutics

Volumn 478, Issue 2, 2015, Pages 540-552

  Ahuja, Bhupesh K ^a   Jena, Sunil K ^a   Paidi, Sharan K ^a   Bagri, Surbhi ^a   Suresh, Sarasija ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Febuxostat; Nanosuspension; Oral bioavailability; Saturation solubility; Stability; Wet media milling

Indexed keywords

FEBUXOSTAT; HYDROXYPROPYLMETHYLCELLULOSE; NANOCRYSTAL; TOCOFERSOLAN; NANOPARTICLE; SUSPENSION; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BEAD VOLUME; CENTRAL COMPOSITE DESIGN; CHEMICAL PARAMETERS; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG SOLUBILITY; DRUG STRUCTURE; EXPERIMENTAL DESIGN; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INVESTIGATIVE PROCEDURES; MAXIMUM PLASMA CONCENTRATION; MILLING TIME; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PH; POLYDISPERSITY INDEX; RAT; SCANNING ELECTRON MICROSCOPY; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; WET MEDIA MILLING; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; MEDICINAL CHEMISTRY; POWDER DIFFRACTION; SOLUBILITY; SPRAGUE DAWLEY RAT;

ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; FEMALE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; POWDER DIFFRACTION; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SUSPENSIONS; THIAZOLES; X-RAY DIFFRACTION;

EID: 84918561251     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.12.003     Document Type: Article

References (51)

1. Bullingham, R.E., Nicholls, A.J., Kamm, B.R., 1998. Clinical pharmacokinetics of mycophenolate mofetil. Clin. Pharmacokinet. 34, 429-455.
2. Chakraborty, S., Shukla, D., Mishra, B., Singh, S., 2009. Lipid - an emerging platform for oral delivery of drugs with poor bioavailability. Eur. J. Pharm. Biopharm. 73, 1-15.
3. Chen, L., Wang, Y., Zhang, J., Hao, L., Guo, H., Lou, H., Zhang, D., 2014. Bexarotene nanocrystal - oral and parenteral formulation development, characterization and pharmacokinetic evaluation. Eur. J. Pharm. Biopharm. 87, 160-169.
4. Davis, T.M., Daly, F., Walsh, J.P., Ilett, K.F., Beilby, J.P., Dusci, L.J., Barrett, P.H.R., 2000. Pharmacokinetics and pharmacodynamics of gliclazide in caucasians and australian aborigines with type 2 diabetes. Br. J. Clin. Pharmacol. 49, 223-230.
5. Ernst, M.E., Fravel, M.A., 2009. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Clin. Ther. 31, 2503-2518.
6. Frick, A., Möller, H., Wirbitzki, E., 1998. Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. Eur. J. Pharm. Biopharm. 46, 305-311.
7. Gao, L., Liu, G., Ma, J., Wang, X., Zhou, L., Li, X., 2012. Drug nanocrystals: in vivo performances. J. Control. Release 160, 418-430.
8. George, M., Ghosh, I., 2013. Identifying the correlation between drug/stabilizer properties and critical quality attributes (CQAs) of nanosuspension formulation prepared by wet media milling technology. Eur. J. Pharm. Sci. 48, 142-152.
9. Ghosh, I., Bose, S., Vippagunta, R., Harmon, F., 2011. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int. J. Pharm. 409, 260-268.
10. Ghosh, I., Schenck, D., Bose, S., Ruegger, C., 2012. Optimization of formulation and process parameters for the production of nanosuspension by wet media milling technique: effect of vitamin E TPGS and nanocrystal particle size on oral absorption. Eur. J. Pharm. Sci. 47, 718-728.
11. Hu, M., Tomlinson, B., 2008. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther. Clin. Risk Manag. 4, 1209-1220.
12. Jackson, C.L., McKenna, G.B., 1990. The melting behavior of organic materials confined in porous solids. J. Chem. Phys. 93, 9002-9011.
13. Jacobs, C., Müller, R.H., 2002. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm. Res. 19, 189-194.
14. Jena, S.K., Singh, C., Dora, C.P., Suresh, S., 2014. Development of tamoxifen-phospholipid complex: novel approach for improving solubility and bioavailability. Int. J. Pharm. 473, 1-9.
15. Joshi, H.N., Tejwani, R.W., Davidovich, M., Sahasrabudhe, V.P., Jemal, M., Bathala, M. S., Varia, S.A., Serajuddin, A., 2004. Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture. Int. J. Pharm. 269, 251-258.
16. Junghanns Jens-Uwe, A.H., Müller, R.H., 2008. Nanocrystal technology: drug delivery and clinical applications. Int. J. Nanomed. 3, 295-310.
17. Kakran, M., Shegokar, R., Sahoo, N.G., Gohla, S., Li, L., Müller, R.H., 2012. Long-term stability of quercetin nanocrystals prepared by different methods. J. Pharm. Pharmacol. 64, 1394-1402.
18. Kalaria, D., Sharma, G., Beniwal, V., Kumar, M.R., 2009. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm. Res. 26, 492-501.
19. Kawakami, K., Oda, N., Miyoshi, K., Funaki, T., Ida, Y., 2006. Solubilization behavior of a poorly soluble drug under combined use of surfactants and cosolvents. Eur. J. Pharm. Sci. 28, 7-14.
20. Kayaert, P., Jimidar, I., Rombaut, P., Ahssini, F., Van den Mooter, G., 2010. Solution calorimetry as an alternative approach for dissolution testing of nanosuspensions. Eur. J. Pharm. Biopharm. 76, 507-513.
21. Khosravan, R., Grabowski, B.A., Wu, J.T., Joseph-Ridge, N., Vernillet, L., 2006. Pharmacokinetics, pharmacodynamics and safety of febuxostat a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin. Pharmacokinet. 45, 821-841.
22. Khosravan, R., Grabowski, B.A., Wu, J.T., Joseph-Ridge, N., Vernillet, L., 2008. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br. J. Clin. Pharmacol. 65, 355-363.
23. Kim, S.C., Kim, D.W., Shim, Y.H., Bang, J.S., Oh, H.S., Kim, S.W., Seo, M.H., 2001. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J. Control. Release 72, 191-202.
24. Lawrence, X.Y., 2008. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm. Res. 25, 781-791.
25. Lindfors, L., Skantze, P., Skantze, U., Rasmusson, M., Zackrisson, A., Olsson, U., 2006. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir 22, 906-910.
26. Liu, P., Rong, X., Laru, J., van Veen, B., Kiesvaara, J., Hirvonen, J., Laaksonen, T., Peltonen, L., 2011. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling. Int. J. Pharm. 411, 215-222.
27. Liversidge, E.M., Liversidge, G.G., 2011. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv. Drug Deliv. Rev. 63, 427-440.
28. Löbenberg, R., Amidon, G.L., 2000. Modern bioavailability: bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50, 3-12.
29. Maddileti, D., Sk, J., Nangia, A., 2013. Soluble cocrystals of the xanthine oxidase inhibitor febuxostat. Cryst. Growth Des. 13, 3188-3196.
30. Merisko-Liversidge, E., Liversidge, G.G., Cooper, E.R., 2003. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18, 113-120.
31. Mishra, P.R., Shaal, L.A., Müller, R.H., Keck, C.M., 2009. Production and characterization of hesperetin nanosuspensions for dermal delivery. Int. J. Pharm. 371, 182-189.
32. Miyako, Y., Khalef, N., Matsuzaki, K., Pinal, R., 2010. Solubility enhancement of hydrophobic compounds by cosolvents: role of solute hydrophobicity on the solubilization effect. Int. J. Pharm. 393, 48-54.
33. Mosharraf, M., Nyström, C., 1995. The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs. Int. J. Pharm. 122, 35-47.
34. Müller, R.H., Jacobs, C., Kayser, O., 2001. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3-19.
35. Müllertz, A., Ogbonna, A., Ren, S., Rades, T., 2010. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J. Pharm. Pharmacol. 62, 1622-1636.
36. Oh, D.M., Curl, R.L., Yong, C.S., Amidon, G.L., 1995. Effect of micronization on the extent of drug absorption from suspensions in humans. Arch. Pharm. Res. 18, 427-433.
37. Peltonen, L., Hirvonen, J., 2010. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J. Pharm. Pharmacol. 62, 1569-1579.
38. Ponchel, G., Montisci, M.J., Dembri, A., Durrer, C., Duchêne, D., 1997. Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur. J. Pharm. Biopharm. 44, 25-31.
39. Rabinow, B.E., 2004. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3, 785-796.
40. Ravichandran, R., 2009. Nanotechnology-based drug delivery systems. NanoBiotechnology 5, 17-33.
41. Savic, I.M., Marinkovic, V.D., Tasic, L., Krajnovic, D., Savic, I.M., 2012. From experimental design to quality by design in pharmaceutical legislation. Accredit. Qual. Assur. 17, 627-633.
42. Schumacher Jr., A.K., 2005. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin. Investig. Drugs 14, 893-903.
43. Shchekin, A.K., Rusanov, A.I., 2008. Generalization of the Gibbs-Kelvin-Köhler and Ostwald-Freundlich equations for a liquid film on a soluble nanoparticle. J. Chem. Phys. 129, 154116.
44. Singare, D.S., Marella, S., Gowthamrajan, K., Kulkarni, G.T., Vooturi, R., Rao, P.S., 2010. Optimization of formulation and process variable of nanosuspension: an industrial perspective. Int. J. Pharm. 402, 213-220.
45. Torchilin, V.P., 2001. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 73, 137-172.
46. Van Eerdenbrugh, B., Froyen, L., Van Humbeeck, J., Martens, J.A., Augustijns, P., Van den Mooter, G., 2008a. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur. J. Pharm. Sci. 35, 127-135.
47. Van Eerdenbrugh, B., Van den Mooter, G., Augustijns, P., 2008b. Top-down production of drug nanocrystals: nanosuspension stabilization: miniaturization and transformation into solid products. Int. J. Pharm. 364, 64-75.
48. Verma, S., Lan, Y., Gokhale, R., Burgess, D.J., 2009. Quality by design approach to understand the process of nanosuspension preparation. Int. J. Pharm. 377, 185-198.
49. Verma, S., Kumar, S., Gokhale, R., Burgess, D.J., 2011. Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening. Int. J. Pharm. 406, 145-152.
50. Wu, L., Zhang, J., Watanabe, W., 2011. Physical and chemical stability of drug nanoparticles. Adv. Drug Deliv. Rev. 63, 456-469.
51. Zirar, S., Gibaud, S., Astier, A., Muchow, M., 2008. Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. Eur. J. Pharm. Biopharm. 70, 649-656.